In late 2023, the first drug with potential to slow the progression of Alzheimer’s disease was approved by the U.S. Federal Drug Administration. Alzheimer’s is one of many debilitating neurological disorders that together affect one-eighth of the world’s population, and while the new drug is a step in the right direction, there is still a long journey ahead to fully understanding it, and other such diseases.”Reconstructing the intricacies of how the human brain functions on a cellular level is one of the biggest challenges in neuroscience,” says Lars Gjesteby, a technical…
